【ECA 新闻】WHO技术报告-生物产品GMP修订

译文：Levi/Avril 校对：Ella

The World Health Organization (WHO) provides a Technical Report Series on their website with guidancedocuments comprising general recommendations for biological products.

世界卫生组织（WHO）在其网站发布了关于生物产品的技术报告系列以及一般建议的指南文件。

Thecurrent document "Good Manufacturing Practices for biological products;Adopted 1991, TRS no 822, Annex 1" is now supposed to be revised. Thus theExpert Committee on Biological Products published a proposed replacement ofthis document. This draft was developed based on the outcomes and consensus ofthe WHO informal consultation convened in July 2014 with participants from nationalregulatory authorities, national control laboratories, manufacturers and academiaresearchers. It is furthermore supposed to include comments from the publicconsultation on the WHO website. Additional comments can be submitted to theWHO until 14 September 2015.

目前计划对现行的文件“生物制品的生产质量管理规范，发布于1991年，技术报告822，附录1”进行修订。因此，生物制品委员会发布了该文件提议的替代文件。该草案的开发是基于WHO在2014年7月和国家监管部门、国家控制实验室、厂家和研究人员参与的非正式会议的结果和共识。除此之外，还包括来自WHO网站上的公共咨询的意见。在2015年9月14日前可以向WHO提供其他的意见。

Thedocument is supposed to serve as a basis and reference/guide for the generationof appropriate/suitable national guidelines. Possibly there will bemodifications/changes necessary in comparison with this document, based on arisk/benefit assessment and legal considerations of the respective nationalauthority.

该文件可以作为出台适当的/合适国家指导方针的基础和参考/指南。基于风险/利益评估和各自国家机构和法规方面的考虑，和本文件相比可能会有必要的修订/修改。

The scope of this guidance document is defined as follows:
本指南文件的范围定义如下：

"Theseguidelines apply to the commercial manufacture, control and testing ofbiological products from starting materials and preparations, including seedlots, cell banks and intermediates, through to the finished products.Manufacturing procedures within the scope of these guidelines include:

“这些指导原则适用于生物制品商业生产、控制和检测，从起始物料和制剂，包括批原料、细胞库和中间产品，一直到成品。在这些指导原则中的生产工艺包括：

• growth of strains of microorganisms and eukaryotic cells

• 微生物菌株和真核细胞的增殖

• extraction of substances from biological tissues, including human, animal and plant tissues and fungi

• 从生物组织中提取的物质，包括人类、动物和植物组织以及真菌

• recombinant DNA (rDNA) techniques

• DNA重组技术

• hybridoma techniques and

• 杂交细胞技术

• propagation of microorganisms in embryos or animals"

• 微生物在胚胎或动物上的增殖

The complete text and contact data for thesubmission of comments can be found at WHOGMP for Biological Products - Proposed replacement of: TRS 822, Annex 1.

完整的文本和提交评论的相关数据可以在WHO GMP for Biological Products - Proposed replacement of: TRS 822,Annex 1找到。

---

奥星GMP合规性及质量管理服务部拥有15年的制药行业验证和GMP咨询经验，与国外的专业验证公司合作，以最新的法规和指南为依据，以质量保证体系为中心，通过强有力的项目管理实施团队，经验丰富的国外顾问和专家，以及全套的验证用仪器为制药行业提供专业而全面的、符合FDA、EU、WHO和中国的GMP要求的验证和GMP咨询服务。迄今为止，我们已经服务几百家制药企业，本着以客户满意为中心的理念，奥星从验证咨询、验证测试、运营卓越咨询、质量体系咨询、注册报批及培训等方面为制药行业提供一站式咨询服务，致力于推动国内制药企业和新兴国家在验证及GMP实施方面达到欧美水平。

长按二维码识别公众号

免责声明：编辑上述内容，对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。仅作参考，并请各位自行承担全部责任。